<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hoyle, Brian</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Zarbin, Marco</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Ranibizumab 0.5 mg Safe and Effective for Treatment of DME</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">8-9</style></pages><abstract><style  face="normal" font="default" size="100%">This article discusses a post hoc analysis of 5 studies of the humanized monoclonal antibody ranibizumab directed against vascular endothelial growth factor-A in the treatment of diabetic macular edema. The analysis focuses on the arterial thromboembolic events associated with ranibizumab that have been reported in controlled clinical trials.</style></abstract><number><style face="normal" font="default" size="100%">43</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>